ESMO Delivers on Dynamic Force Strategy to Improve Cancer Research in Europe
New website section dedicated to research funding opportunities created to promote and improve clinical cancer research in Europe
ESMO Media Releases
High-dose interleukin-2 effective in mRCC pre-treated with VEGF-targeted therapies
High-dose interleukin-2 can be effective in selected metastatic renal cell cancer patients pre-treated with VEGF-targeted agents, reveals research presented today at the ESMO Symposium on Immuno-Oncology in Geneva, Switzerland.
Immune Checkpoint Inhibitors May Work in Brain Cancer
New evidence that immune checkpoint inhibitors may work in glioblastoma and brain metastases was presented today by Dr Anna Sophie Berghoff at the ESMO Symposium on Immuno-Oncology 2014 in Geneva, Switzerland
Possibilities for Personalised Vaccines Revealed at ESMO Symposium
The possibilities for personalised vaccines in all types of cancer are revealed today in a lecture from Dr Harpreet Singh at the ESMO Symposium on Immuno-Oncology 2014 in Geneva, Switzerland
Immunotherapy Set to Revolutionise Cancer Treatment
Immunotherapy is set to revolutionise the treatment of cancer, according to ESMO President Professor Rolf A. Stahel. His comments come as the ESMO Symposium on Immuno-Oncology 2014 is about to open in Geneva, Switzerland tomorrow.
ESMO Announces Annual Medical Oncology Congress Platform in Europe from 2016
ESMO announced today that it will be organising an annual Congress in Europe starting in 2016
Cancer Medicine Becoming Ever More Precise, Practice-Changing Results at ESMO 2014 Show
A record number of 19,859 attendees at the ESMO 2014 Congress discussed changes to oncology that will soon have a positive impact on the care of patients around the world.
Anti-PD-L1 Antibody Shows Promising Activity in Advanced Bladder Cancer after Decades of Silence
Corrigendum: Please note the updated data for the response rate is 52% instead of 43%
PIK3CA Mutations Blunt Benefit of Anti-HER2 Drugs
Patients with HER2 positive breast cancer derive less benefit from anti-HER2 drugs when they have PIK3CA mutations
RAS Testing Only the First Step for Choosing Treatment for Metastatic Colorectal Cancer, Important New Data Show
Important new data from two trials evaluating different treatment approaches in metastatic colorectal cancer provide reassurance for clinicians that current treatment choices are valid, and confirm that molecular characterisation of such tumours is vital
Promising Results Shown with Targeted Approaches in Subsets of Non-Small-Cell Lung Cancer
Dabrafenib anti-tumour activity in BRAF V600E mutation-positive non-small cell lung cancer; HER2 inhibition shows promise in HER2-positive non-small cell lung cancer